logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Genomics
Filter

Genomics

Categories

Sectors

Locations

Exchange

世卫组织:正在研制至少20种新冠病毒疫苗,确保人人接种

WHO officials say at least 20 coronavirus vaccines are in development in global race for cure

Mar 20, 2020

Life Science

梯瓦制药 冠状病毒 疟疾药物,意大利 疫情

Healthcare Roundup – Teva to donate 6M doses of malaria drug for coronavirus use, Italy now world’s #1 Covid-19 hotspot

Mar 20, 2020

Life Science

新冠病毒 中国 疫苗 试验

First-Phase Clinical Trials of China’s First Covid-19 Vaccine to Last Nine Months

Mar 19, 2020

Life Science

法维拉韦获治疗新冠病毒推荐,海正药业走红

Favilavir’s Covid-19 Effectiveness Boosts Hisun Pharma, Fujifilm Stock to Limit

Mar 19, 2020

Life Science

再鼎医药 则乐(尼拉帕利) 卵巢癌

(Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA

Mar 18, 2020

Life Science

诺诚健华 香港上市

China biotech InnoCare raises $288 million in Hong Kong IPO: sources

Mar 17, 2020

Life Science

BioELife 新冠病毒 CytoDyn PRO 140

Healthcare Roundup – BioELife expands COVID-19 prevention product line, CytoDyn advancing mid-stage study of PRO 140 for COVID-19

Mar 17, 2020

Life Science

复星 BioNTech 新冠病毒

BioNTech and Fosun to Develop mRNA Vaccine for COVID-19

Mar 16, 2020

Life Science

特朗普 全国紧急状态 新冠病毒 吉利德 瑞德昔韦

Healthcare Roundup – President Trump declares national emergency over coronavirus, Gilead up 6% premarket on encouraging action of remdesivir in COVID-19

Mar 13, 2020

Life Science

和铂医药完成7500万美元B+轮融资

Harbour BioMed Secures $85 Million in Financing Round to Support Clinical-Stage Compounds

Mar 12, 2020

Life Science

FDA加速批准纳武利尤单抗联合伊匹木单抗

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib

Mar 12, 2020

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Japan’s Regulatory Agency, PMDA, Clears RepliCel Life Sciences to Proceed to Final Consultation for Tendon and Skin Cell Therapy Products

Mar 11, 2020

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Japan’s Patent Office Issues RepliCel Two New Patents for its Regenerative Medicine Technologies

Mar 10, 2020

Life Science

中国上海奥浦迈完成1400万美元新一轮融资

Shanghai OPM Bio Raises $14 Million for Biologic CDMO Service Platform

Mar 9, 2020

Life Science

Production of Dermal Injectors Delayed by China Work Stoppage Effecting Critical Component

Mar 9, 2020

Life Science

Cocrystal Pharma Gilead COVID-19 coronavirus

Healthcare Roundup – Cocrystal Pharma up 36% after hours on launch of coronavirus program, Gilead up 3% ahead of expected COVID-19 drug data readout

Mar 7, 2020

Life Science

Beroni Group 天津大学

Beroni Group Collaborates with Tianjin University to Develop Novel Solution for Coronavirus (COVID-19)

Feb 20, 2020

Life Science

北京安智因 融资

Anngeen Technolgies Raises $14 Million for Clinical Genetic Diagnosis Operations

Feb 19, 2020

Life Science

  • ‹‹ Previous
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada